Can a tailored trial help heart patients decide on Beta-Blockers?

NCT ID NCT05585125

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether a personalized 'N-of-1' trial can help older adults with a type of heart failure (HFpEF) decide if they want to continue or stop taking beta-blockers. Twenty participants will go through periods on and off their beta-blocker, in a random order, to see how it affects their confidence and decision-making. The goal is to find a practical way to optimize medications for each individual.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
beta blocker (acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol)
What this could lead to
If successful, this could show that personalized N-of-1 trials help patients and doctors make better decisions about continuing or stopping beta-blockers.
What could go wrong
This is a very small, early-phase study with only 20 participants, focused on decision-making rather than health outcomes. Results may not apply to everyone with heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.